Array BioPharma Inc.
(NASDAQ GM: ARRY)
Attention investors who purchased shares of Array BioPharma Inc. before June 17, 2019:
Rigrodsky & Long is investigating potential claims against the board of directors of Array BioPharma Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Pfizer Inc. for $48.00 per share, or approximately $11.4 billion.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Array BioPharma Inc. (“Array” or the “Company”) (NASDAQ GM: ARRY) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Pfizer Inc. (“Pfizer”) (NYSE: PFE), in a transaction valued at approximately $11.4 billion. Under the terms of the agreement, shareholders of Array will receive $48.00 in cash for each share of Array common stock.
If you own common stock of Array and purchased any shares before June 17, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.